STOCK TITAN

Vision Sensing Acquisition Corp - VSACU STOCK NEWS

Welcome to our dedicated news page for Vision Sensing Acquisition (Ticker: VSACU), a resource for investors and traders seeking the latest updates and insights on Vision Sensing Acquisition.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vision Sensing Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vision Sensing Acquisition's position in the market.

Rhea-AI Summary
Vision Sensing Acquisition Corp. (NASDAQ: VSAC) filed Form 10-Q with the SEC, curing filing delinquency and staying suspension of securities. Nasdaq Hearing Panel decision awaited on April 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
acquisition
-
Rhea-AI Summary
Vision Sensing Acquisition Corp. (NASDAQ: VSAC) filed Form 10-Q with the SEC, curing filing delinquency and staying suspension of securities. Nasdaq Hearing Panel decision awaited on April 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) has extended the date for its initial business combination with Mediforum Co. Ltd., a Korean company, by depositing $60,000 into its trust account. This is the fourth of up to six one-month extensions authorized by the company's amended and restated certificate of incorporation. The extension provides the company with additional time to complete the merger agreement with Mediforum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
Rhea-AI Summary
Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) has extended the date for its initial business combination with Mediforum Co. Ltd., a Korean company, by depositing $60,000 into its trust account. This is the fourth of up to six one-month extensions authorized by the company's amended and restated certificate of incorporation. The extension provides the company with additional time to complete the merger agreement with Mediforum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
Vision Sensing Acquisition Corp. (VSAC) has announced an extension of the date to consummate its initial business combination to March 3, 2024, with its sponsor depositing $60,000 into the trust account by February 3, 2023. The Company intends to issue a non-interest bearing, unsecured promissory note to its sponsor as consideration for the funding. This extension is the fourth of up to six one-month extensions authorized under its amended certificate of incorporation. The extension provides additional time to complete its initial business combination with Mediforum Co. Ltd., a Korean company, pursuant to a merger agreement dated January 12, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
Vision Sensing Acquisition Corp. (VSAC) has announced an extension of the date to consummate its initial business combination to March 3, 2024, with its sponsor depositing $60,000 into the trust account by February 3, 2023. The Company intends to issue a non-interest bearing, unsecured promissory note to its sponsor as consideration for the funding. This extension is the fourth of up to six one-month extensions authorized under its amended certificate of incorporation. The extension provides additional time to complete its initial business combination with Mediforum Co. Ltd., a Korean company, pursuant to a merger agreement dated January 12, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
Rhea-AI Summary
Vision Sensing Acquisition Corp. issues an update regarding the previously announced staff determination letter from Nasdaq, notifying the Company of non-compliance with market value and total holders requirements. The Company submitted an appeal and a detailed Compliance Plan to regain compliance, with a hearing scheduled for April 4, 2024. The deficiencies are common for SPACs at the Company's current stage, and the recently announced business combination with Mediforum Co., Ltd. is expected to automatically resolve these deficiencies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
Vision Sensing Acquisition Corp. (VSAC) received a staff determination letter from Nasdaq, stating the intention to delist the company's securities due to non-compliance with listing requirements. The company has not regained compliance with the market value and total holders requirements. Unless an appeal is requested, trading of the company's shares will be suspended on January 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
Vision Sensing Acquisition Corp. (VSAC) received a staff determination letter from Nasdaq, stating the intention to delist the company's securities due to non-compliance with listing requirements. The company has not regained compliance with the market value and total holders requirements. Unless an appeal is requested, trading of the company's shares will be suspended on January 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
Rhea-AI Summary
Mediforum, a leading biotechnology company in Korea, specializing in ethical drug development, is merging with Vision Sensing Acquisition Corp. (VSAC) to become a publicly listed company on NASDAQ under a new ticker symbol. Mediforum is focused on developing drugs for Alzheimer’s Disease and Chemotherapy-Induced Peripheral Neuropathy, with PM012 and MF018 in Phase 2b and Phase 2 clinical trials, respectively. The pre-money enterprise value of Mediforum is US$250 million, with plans for additional financing of up to US$50 million from private placement of equity, debt, or alternative financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
Vision Sensing Acquisition Corp

Nasdaq:VSACU

VSACU Rankings

VSACU Stock Data

1.82M
0%
Shell Companies
Financial Services
United States
Miami